Adam Simpson

Icosavax posts COVID-19 vaccine knowledge ‘beneath our expectations’ as shares plummet greater than 60%

An image of the nanoparticle with spike proteins used in Icosavax’s COVID-19 vaccine candidate. (Ian Haydon, UW Institute for Protein…